Cargando…

Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149

Resistance to platinum-based chemotherapy becomes a major obstacle in non-small-cell lung cancer (NSCLC) treatment. Overexpression of the excision repair cross-complementing 1 (ERCC1) gene is reported to negatively influence the effectiveness of cisplatin-based therapy for NSCLC cells. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yuwen, Chen, Danyang, Yi, Yanmei, Zeng, Shanshan, Liu, Shuang, Li, Pan, Xie, Hui, Yu, Pengjiu, Jiang, Guanmin, Liu, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251316/ https://www.ncbi.nlm.nih.gov/pubmed/32478168 http://dx.doi.org/10.1016/j.omto.2020.05.001

Ejemplares similares

MiR‐149 sensitizes esophageal cancer cell lines to cisplatin by targeting DNA polymerase β
por: Wang, Yuanyuan, et al.
Publicado: (2018)

miR-149-5p Inhibits Vascular Smooth Muscle Cells Proliferation, Invasion, and Migration by Targeting Histone Deacetylase 4 (HDAC4)
por: Zhang, Boya, et al.
Publicado: (2019)

MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells
por: Xie, Xiaoque, et al.
Publicado: (2019)

Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together
por: Wawruszak, Anna, et al.
Publicado: (2021)

Dinitrosopiperazine‐decreased PKP3 through upregulating miR‐149 participates in nasopharyngeal carcinoma metastasis
por: Li, Yuejin, et al.
Publicado: (2018)

Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer
por: Xie, Kejie, et al.
Publicado: (2021)

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells
por: Guo, Jiwei, et al.
Publicado: (2018)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells
por: Zhang, Baojie, et al.
Publicado: (2019)

Histone deacetylase mediated silencing of AMWAP expression contributes to cisplatin nephrotoxicity
por: Ranganathan, Punithavathi, et al.
Publicado: (2016)

New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells
por: Gueugnon, Fabien, et al.
Publicado: (2014)

MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2
por: Zhao, Henan, et al.
Publicado: (2016)

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
por: Obiedat, Hadeel, et al.
Publicado: (2018)

The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines
por: Kim, Min-Gyun, et al.
Publicado: (2012)

Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line
por: Zhang, Xuan, et al.
Publicado: (2015)

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus
por: Hulin-Curtis, Sarah L., et al.
Publicado: (2018)

Sulforaphane attenuates cisplatin-induced hearing loss by inhibiting histone deacetylase expression
por: Wang, Jie, et al.
Publicado: (2021)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Overexpression of miR-140 Inhibits Proliferation of Osteosarcoma Cells via Suppression of Histone Deacetylase 4
por: Xiao, Qianren, et al.
Publicado: (2017)

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression
por: Usanova, Svetlana, et al.
Publicado: (2010)

Histone deacetylase inhibitors protect against cisplatin-induced acute kidney injury by activating autophagy in proximal tubular cells
por: Liu, Jing, et al.
Publicado: (2018)

MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A
por: Wang, Jin, et al.
Publicado: (2021)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells
por: Kapoor, Sabeeta, et al.
Publicado: (2021)

miR-149-3p reverses CD8(+) T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells
por: Zhang, Meng, et al.
Publicado: (2019)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Clinical Significance of miR-149 in the Survival of Patients with Laryngeal Squamous Cell Carcinoma
por: Xu, Yi, et al.
Publicado: (2016)

miR-149 in Human Cancer: A Systemic Review
por: He, Yunjie, et al.
Publicado: (2018)

Role of Histone Deacetylases in T-Cell Development and Function
por: Pieniawska, Monika, et al.
Publicado: (2022)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Statins and Histone Deacetylase Inhibitors Affect Lamin A/C – Histone Deacetylase 2 Interaction in Human Cells
por: Mattioli, Elisabetta, et al.
Publicado: (2019)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
por: Freese, Kim, et al.
Publicado: (2019)

Glioma Stem Cells Are Sensitized to BCL-2 Family Inhibition by Compromising Histone Deacetylases
por: Merati, Aran, et al.
Publicado: (2023)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene
por: Liu, Yu-Chin, et al.
Publicado: (2015)

Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy
por: Blattmann, Claudia, et al.
Publicado: (2015)

Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy
por: Haery, Leila, et al.
Publicado: (2015)

miR-1271 enhances the sensitivity of colorectal cancer cells to cisplatin
por: Yao, Huixiang, et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

MiR-222 Targeted PUMA to Improve Sensitization of UM1 Cells to Cisplatin
por: Jiang, Fangfang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9q1hdl8ffr25i448nhb8us3lfp